Algernon Pharmaceuticals Inc (AGNPF)

[tcm55]

near term events. Hmmmmmmmm...

With good feedback from the pre IND meeting with the FDA about the SCLC/pancreatic tumor trials,, what happens next.?.

https://www.globenewswire.com/news-release/2021/11/24/2340463/0/en/Algernon-Pharmaceuticals-Announces-Positive-Feedback-from-U-S-FDA-for-Phase-1-Ifenprodil-Small-Cell-Lung-Cancer-Study.htm

Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
VANCOUVER, British Columbia, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical development company, is pleased to announce that it has completed enrollment in its Phase 2 NP-120 (“Ifenprodil”) idiopathic pulmonary fibrosis (“IPF’) and chronic cough study. The Company is projecting a data readout in calendar Q2, 2022.

https://www.globenewswire.com/news-release/2022/01/28/2374942/0/en/Algernon-Pharmaceuticals-Announces-Notice-of-Allowance-for-Ifenprodil-Patent-Application-for-Idiopathic-Pulmonary-Fibrosis.html

https://www.otcmarkets.com/stock/AGNPF/news/Algernon-Pharmaceuticals-Announces-Positive-Feedback-from-US-FDA-for-Phase-2b-Ifenprodil-Chronic-Cough-Study?id=339117


UK MHRA decision/approval of the Stroke Phase 1 clinical trial.
Dr Simister, Dr Rudd, Dr Nutt, Dr Strassman.!.!.!.

l

With IBD and CKD drugs from NASH for other future paths of long term value. Hmmm...GLTA...